First AI-based Cancer Detection Application Slated for UK Rollout

First AI-based Cancer Detection Application Slated for UK Rollout
Ibex Medical Analytics and LDPath have announced the rollout of the first clinical-grade artificial intelligence (AI) applications for pathology-based prostate cancer detection in the U.K.  The new apps will aid in improving the accuracy and increasing the efficiency of cancer diagnostics, the companies said. Traditionally, cancer is diagnosed with the aid of a pathologist — an expert who will look at tissue samples under a microscope to identify changes associated with diseases. In recent years, the number of pathologists around the world has decreased, even as the global incidence of cancer has increased. The limited availability of pathologists has ultimately resulted in diagnostic delays for many people with cancer.  These delays are further exacerbated by the fact that a lot of traditional pathology reporting still is done using paper and ink, even in this digital age. Further, having people — even trained experts — analyze tissue samples means that the analyses will be subject to human biases and errors. That raises the likelihood of improper diagnoses, especially with the increased pressure put on the limited number of working pathologists. One solution to this problem is to implement AI-based approaches to tissue analysis. Essentially, that means using sophisticated algorithms to detect any pathological changes in tissue, as a pathologist would typically do. "Cancer cases continue to rise, and with the pathology practice experiencing a worldwide shortage, AI-based technologies can drive new workflows for pathology that will be critical for improving cancer care practices for patients, pathologists, labs and entire healthcare systems," Joseph Mossel, CEO and co-founder of Ibex, said in a press release. Ibex's Galen platform is an AI
Subscribe or to access all post and page content.